US Stem Cell's market cap is currently ―. The company's EPS TTM is $-0.005; its P/E ratio is -2.00; US Stem Cell is scheduled to report earnings on August 7, 2019, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 8.05K	$ 10.66K	$ 24.52K	$ 23.31K	$ 23.59K
Gross Profit	$ 15.05K	$ 8.98K	$ 18.27K	$ 15.97K	$ 14.96K
EBIT	$ -374.92K	$ -396.62K	$ -394.57K	$ -1.00M	$ -125.08K
EBITDA	$ -182.49K	$ -227.84K	$ -394.57K	$ -1.00M	$ -125.08K
Net Income Common Stockholders	$ 3.03M	$ -565.37K	$ -570.10K	$ -1.16M	$ -641.02K
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 5.13K	$ 30.16K	$ 10.33K	$ 14.47K	$ 39.39K
Total Assets	$ 68.04K	$ 171.89K	$ 71.10K	$ 142.36K	$ 51.00K
Total Debt	$ 8.95M	$ 8.75M	$ 8.56M	$ 8.41M	$ 8.02M
Net Debt	$ 8.94M	$ 8.72M	$ 8.55M	$ 8.39M	$ 7.98M
Total Liabilities	$ 14.81M	$ 14.37M	$ 13.93M	$ 13.51M	$ 12.82M
Stockholders Equity	$ -14.75M	$ -14.20M	$ -13.86M	$ -13.37M	$ -12.77M
Cash Flow	-
Free Cash Flow	$ -43.06K	$ -64.67K	$ -133.31K	$ -63.81K	$ -216.70K
Operating Cash Flow	$ -43.06K	$ -64.67K	$ -133.31K	$ -63.81K	$ -216.70K
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	$ 18.04K	$ 84.50K	$ 129.17K	$ 38.88K	$ 225.76K

Currency in USD

US Stem Cell Earnings and Revenue History

Income Statement >

US Stem Cell Debt to Assets

Balance Sheet >

US Stem Cell Cash Flow

Cash Flow >

US Stem Cell Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing